Page 9 - Scientific Library
Live Cell Imaging: User results with SiR-Actin & SiR-Tubulin
For one year now,  SiR-Actin and SiR-Tubulin, the second generation of tools to stain actin and tubulin in living cells, have been available on the market - and although it may sound like an overstatement,
Angiogenin favours liver cancer (HCC) growth & expansion
A publication earlier this year by Bárcena et al. shows that angiogenin plays a crucial role in the onset and development of liver cancer (hepatocellular carcinoma or HCC).
Angiogenin was the first
IDO and TDO - Cell based & biochemical assays
Â
Which roles do IDO and TDO play in Immunotherapy? Immune evasion is one of the identifying hallmarks of cancer and researchers are investigating the complex mechanisms that enable cancer cells to evade
Biomarkers associated to poor prognosis in pancreatic cancer
A recent publication by Torres et al. has found that B7-1/CD80, EG-VEGF/PK1, IL-29, NRG1-beta1/HRG1-beta1, and PD-ECGF expressions portend a poor prognosis for patients with pancreatic cancer, and these
Immunotherapy Screening – OX40:OX40L pathway
The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory
Crosstalk between cancer and immune cells: tumor escape
A crosstalk between cancer and immune cells is established during cancers. The immune system is able to fight against tumour cells (see my previous post "Immunosurveillance: Crosstalk between cancer
3 easy colorimetric assays to measure ECM components
Matrix components are key R&D elements in pharmaceutical and cosmetology with tremendous impacts on tissue regeneration, skin repair, wound healing, allergy
Cancer and immune cells crosstalk: immunoediting
Immunoediting of cytokine signals provides another area of pathways which tumours utilise to evade and potentially escape from immunological targeting. This post aims at shedding some light into the
Which Histone (De)Methyltransferase modulators to choose?
Histone Methyltransferases (ex. EZH1 and EZH2, and G9a) and their counter-parts (Histone demethylases like JARID1, the KDM4, and the JMJD family) have become promising targets for inhibitor screenings,